US FDA approvals reach all-time high in 2015

28 March 2016
biosimilars_samples_large

In 2015, the US Food and Drug Administration set a new record for the number of drugs approved in one year, with 56 drugs getting the green light from the federal agency.

Last year’s therapies, approved through the FDA’s drug and biologics divisions, included 33 specialty drugs and 23 traditional drugs, according to a report by leading US pharmacy management firm Express Scripts. The previous record number of FDA approvals was in 1996 with 53 drugs gaining clearance.

Specialty drugs to treat rare conditions, as well as complex diseases such as cancer, have accounted for the majority of FDA approvals for the past five years as drug manufacturers devote more time and money to developing specialized treatments. While the majority of drugs to gain approval in 2015 were specialty drugs, several new traditional drugs to treat heart failure present new treatment options for millions of Americans. With new treatments for heart failure and high cholesterol, as well as the first biosimilar to gain approval, 2015 was a blockbuster year for drugs to gain FDA approval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biosimilars